

# Joseph W Polli

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/9006465/joseph-w-polli-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

51  
papers

6,118  
citations

34  
h-index

55  
g-index

55  
ext. papers

6,562  
ext. citations

6.2  
avg, IF

4.68  
L-index

#	Paper	IF	Citations
51	Mechanistic Basis of Cabotegravir-Glucuronide Disposition in Humans. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2019</b> , 370, 269-277	4.7	3
50	Hepatobiliary Disposition of Atovaquone: A Case of Mechanistically Unusual Biliary Clearance. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2018</b> , 366, 37-45	4.7	1
49	Disease-Associated Changes in Drug Transporters May Impact the Pharmacokinetics and/or Toxicity of Drugs: A White Paper From the International Transporter Consortium. <i>Clinical Pharmacology and Therapeutics</i> , <b>2018</b> , 104, 900-915	6.1	53
48	Drug interaction profile of the HIV integrase inhibitor cabotegravir: assessment from in vitro studies and a clinical investigation with midazolam. <i>Xenobiotica</i> , <b>2016</b> , 46, 445-56	2	31
47	Breast cancer resistance protein (ABCG2) in clinical pharmacokinetics and drug interactions: practical recommendations for clinical victim and perpetrator drug-drug interaction study design. <i>Drug Metabolism and Disposition</i> , <b>2015</b> , 43, 490-509	4	91
46	Understanding the transport properties of metabolites: case studies and considerations for drug development. <i>Drug Metabolism and Disposition</i> , <b>2014</b> , 42, 650-64	4	42
45	First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitus. <i>BMC Pharmacology &amp; Toxicology</i> , <b>2013</b> , 14, 26	2.6	32
44	Safety, pharmacokinetics and pharmacodynamics of remogliflozin etabonate, a novel SGLT2 inhibitor, and metformin when co-administered in subjects with type 2 diabetes mellitus. <i>BMC Pharmacology &amp; Toxicology</i> , <b>2013</b> , 14, 25	2.6	26
43	Central nervous system disposition and metabolism of Fosdevirine (GSK2248761), a non-nucleoside reverse transcriptase inhibitor: an LC-MS and Matrix-assisted laser desorption/ionization imaging MS investigation into central nervous system toxicity. <i>Chemical Research in Toxicology</i> , <b>2013</b> , 26, 241-51	4	62
42	In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor. <i>Drug Metabolism and Disposition</i> , <b>2013</b> , 41, 353-61	4	155
41	ADME Pharmacogenomics in Drug Development <b>2013</b> , 13-37		3
40	Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design. <i>Xenobiotica</i> , <b>2013</b> , 43, 498-508	2	38
39	Lapatinib distribution in HER2 overexpressing experimental brain metastases of breast cancer. <i>Pharmaceutical Research</i> , <b>2012</b> , 29, 770-81	4.5	163
38	Assessment of the drug interaction risk for remogliflozin etabonate, a sodium-dependent glucose cotransporter-2 inhibitor: evidence from in vitro, human mass balance, and ketoconazole interaction studies. <i>Drug Metabolism and Disposition</i> , <b>2012</b> , 40, 2090-101	4	24
37	Assessment of Remogliflozin Etabonate, a Sodium-Dependent Glucose Co-Transporter-2 Inhibitor, as a Perpetrator of Clinical Drug Interactions: A Study on Drug Transporters and Metabolic Enzymes. <i>Journal of Diabetes &amp; Metabolism</i> , <b>2012</b> , 03,	0	6
36	Response from the International Transporter Consortium. <i>Nature Reviews Drug Discovery</i> , <b>2011</b> , 10, 75-76	4.1	4
35	Membrane transporters in drug development. <i>Nature Reviews Drug Discovery</i> , <b>2010</b> , 9, 215-36	64.1	2464

34	If the KI is defined by the free energy of binding to P-glycoprotein, which kinetic parameters define the IC50 for the Madin-Darby canine kidney II cell line overexpressing human multidrug resistance 1 confluent cell monolayer?. <i>Drug Metabolism and Disposition</i> , <b>2010</b> , 38, 260-9	4	26
33	Use of cassette dosing in sandwich-cultured rat and human hepatocytes to identify drugs that inhibit bile acid transport. <i>Toxicology in Vitro</i> , <b>2010</b> , 24, 297-309	3.6	34
32	Toxicity and toxicokinetics of metformin in rats. <i>Toxicology and Applied Pharmacology</i> , <b>2010</b> , 243, 340-7	4.6	57
31	Oral sulfasalazine as a clinical BCRP probe substrate: pharmacokinetic effects of genetic variation (C421A) and pantoprazole coadministration. <i>Journal of Pharmaceutical Sciences</i> , <b>2010</b> , 99, 1046-62	3.9	44
30	An unexpected synergist role of P-glycoprotein and breast cancer resistance protein on the central nervous system penetration of the tyrosine kinase inhibitor lapatinib (N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine; GW572016). <i>Drug Metabolism and Disposition</i> , <b>2009</b> , 37, 439-42	4	214
29	Biopharmaceutics classification system: validation and learnings of an in vitro permeability assay. <i>Molecular Pharmaceutics</i> , <b>2009</b> , 6, 11-8	5.6	75
28	The ABCG2 C421A polymorphism does not affect oral nitrofurantoin pharmacokinetics in healthy Chinese male subjects. <i>British Journal of Clinical Pharmacology</i> , <b>2008</b> , 66, 233-9	3.8	37
27	Kinetic identification of membrane transporters that assist P-glycoprotein-mediated transport of digoxin and loperamide through a confluent monolayer of MDCKII-hMDR1 cells. <i>Drug Metabolism and Disposition</i> , <b>2008</b> , 36, 452-60	4	51
26	PhRMA white paper on ADME pharmacogenomics. <i>Journal of Clinical Pharmacology</i> , <b>2008</b> , 48, 849-89	2.9	58
25	The role of efflux and uptake transporters in [N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine (GW572016, lapatinib) disposition and drug interactions. <i>Drug Metabolism and Disposition</i> , <b>2008</b> , 36, 695-701		
24	In vitro p-glycoprotein inhibition assays for assessment of clinical drug interaction potential of new drug candidates: a recommendation for probe substrates. <i>Drug Metabolism and Disposition</i> , <b>2006</b> , 34, 786-92	4	235
23	P-Glycoprotein (P-gp) expressed in a confluent monolayer of hMDR1-MDCKII cells has more than one efflux pathway with cooperative binding sites. <i>Biochemistry</i> , <b>2006</b> , 45, 15505-19	3.2	24
22	The elementary mass action rate constants of P-gp transport for a confluent monolayer of MDCKII-hMDR1 cells. <i>Biophysical Journal</i> , <b>2005</b> , 88, 715-38	2.9	57
21	The steady-state Michaelis-Menten analysis of P-glycoprotein mediated transport through a confluent cell monolayer cannot predict the correct Michaelis constant Km. <i>Pharmaceutical Research</i> , <b>2005</b> , 22, 1667-77	4.5	48
20	Multiple mechanisms are involved in the biliary excretion of acetaminophen sulfate in the rat: role of Mrp2 and Bcrp1. <i>Drug Metabolism and Disposition</i> , <b>2005</b> , 33, 1158-65	4	61
19	Steady-state brain concentrations of antihistamines in rats: interplay of membrane permeability, P-glycoprotein efflux and plasma protein binding. <i>Pharmacology</i> , <b>2004</b> , 72, 92-8	2.3	58
18	The systemic exposure of an N-methyl-D-aspartate receptor antagonist is limited in mice by the P-glycoprotein and breast cancer resistance protein efflux transporters. <i>Drug Metabolism and Disposition</i> , <b>2004</b> , 32, 722-6	4	28
17	Predicting P-glycoprotein substrates by a quantitative structure-activity relationship model. <i>Journal of Pharmaceutical Sciences</i> , <b>2004</b> , 93, 957-68	3.9	92

16	Exact kinetic analysis of passive transport across a polarized confluent MDCK cell monolayer modeled as a single barrier. <i>Journal of Pharmaceutical Sciences</i> , <b>2004</b> , 93, 2108-23	3.9	54
15	In vitro absorption and secretory quotients: practical criteria derived from a study of 331 compounds to assess for the impact of P-glycoprotein-mediated efflux on drug candidates. <i>Journal of Pharmaceutical Sciences</i> , <b>2004</b> , 93, 2567-72	3.9	17
14	Midazolam exhibits characteristics of a highly permeable P-glycoprotein substrate. <i>Pharmaceutical Research</i> , <b>2003</b> , 20, 757-64	4.5	53
13	P-glycoprotein influences the brain concentrations of cetirizine (Zyrtec), a second-generation non-sedating antihistamine. <i>Journal of Pharmaceutical Sciences</i> , <b>2003</b> , 92, 2082-9	3.9	70
12	Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2002</b> , 303, 1029-37	4.7	512
11	Prospective CYP2D6 genotyping as an exclusion criterion for enrollment of a phase III clinical trial. <i>Pharmacogenetics and Genomics</i> , <b>2000</b> , 10, 583-90		39
10	Influence of passive permeability on apparent P-glycoprotein kinetics. <i>Pharmaceutical Research</i> , <b>2000</b> , 17, 1456-60	4.5	102
9	Vitamin E-TPGS increases absorption flux of an HIV protease inhibitor by enhancing its solubility and permeability. <i>Pharmaceutical Research</i> , <b>1999</b> , 16, 1812-7	4.5	170
8	Role of P-glycoprotein on the CNS disposition of amprenavir (141W94), an HIV protease inhibitor. <i>Pharmaceutical Research</i> , <b>1999</b> , 16, 1206-12	4.5	188
7	P-glycoprotein-mediated transport of morphine in brain capillary endothelial cells. <i>Biochemical Pharmacology</i> , <b>1999</b> , 58, 951-7	6	90
6	Expression of calmodulin-dependent enzymes in developing rat striatum is not affected by perturbation of dopaminergic systems. <i>Synapse</i> , <b>1991</b> , 9, 136-43	2.4	6
5	Expression of the calmodulin-dependent protein phosphatase, calcineurin, in rat brain: developmental patterns and the role of nigrostriatal innervation. <i>Developmental Brain Research</i> , <b>1991</b> , 63, 105-19		68
4	[53] Identification of calmodulin-binding proteins. <i>Methods in Enzymology</i> , <b>1990</b> , 184, 451-467	1.7	13
3	Developmental expression of calmodulin-dependent cyclic nucleotide phosphodiesterase in rat brain. <i>Developmental Brain Research</i> , <b>1990</b> , 53, 253-63		27
2	Developmental expression of neuronal calmodulin-binding proteins in rat brain. <i>Developmental Brain Research</i> , <b>1990</b> , 53, 62-70		9
1	Expression of calmodulin-dependent phosphodiesterase, calmodulin-dependent protein phosphatase, and other calmodulin-binding proteins in human SMS-KCNR neuroblastoma cells. <i>Journal of Neurochemistry</i> , <b>1989</b> , 52, 1438-48	6	6